Degree of kidney injury due to artificial pelvic-ureteric junction obstruction with level of neutrophil gelatinase-associated lipocalin, interleukin 18, and histopathological descriptions in Wistar: experimental research.
Histopathology
IL-18
NGAL
ureteropelvic junction obstruction
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
10
03
2023
accepted:
24
04
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Pelvic-ureteric junction obstruction (PUJO) is considered the most common pathology for hydronephrosis in neonates. Full recovery of kidney impairment due to PUJO is possible, especially when pyeloplasty is indicated as surgery is mostly conducted when deterioration is identified, early detection should be considered to prevent further complications. Commonly used kidney damage biomarkers are not sensitive enough to predict kidney damage. Neutrophil gelatinase-associated lipocalin (NGAL) and urinary interleukin 18 (IL-18) are markers of early kidney damage with different characteristics. This study aimed to evaluate the relationship between these two markers with the degree of histopathological kidney damage in Wistar rats induced by PUJO. A total of thirty male Wistar rats, 200-250 g, were divided into three groups: (1) control, (2) sham, (3) PUJO (4th, 7th, 14th, and 21st days). Urine NGAL, IL-18 levels, and renal histopathology were observed on day 0, 4, 7, 14, and 21. Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney test with There was no significant difference in urine NGAL levels between groups, while IL-18 levels were significantly different based on the Kruskal-Wallis test ( Urinary IL-18 levels can be used as a predictor of kidney damage in acute-subacute PUJO cases.
Identifiants
pubmed: 37363465
doi: 10.1097/MS9.0000000000000770
pii: AMSU-D-23-00493
pmc: PMC10289578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2647-2654Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
None declared.
Références
Hypertension. 2004 Apr;43(4):722-3
pubmed: 14967828
J Leukoc Biol. 2003 Feb;73(2):213-24
pubmed: 12554798
J Nephrol. 2015 Feb;28(1):7-16
pubmed: 24899123
Pediatr Nephrol. 2011 Apr;26(4):579-86
pubmed: 21279810
N Am J Med Sci. 2010 Apr;2(4):170-3
pubmed: 22624135
Open Access J Urol. 2010 Apr 22;2:41-55
pubmed: 24198613
Children (Basel). 2021 Feb 04;8(2):
pubmed: 33557240
J Pharmacol Exp Ther. 2012 Jun;341(3):656-62
pubmed: 22399813
J Am Soc Nephrol. 2011 Jan;22(1):165-75
pubmed: 21071523
Am J Kidney Dis. 2009 Dec;54(6):1012-24
pubmed: 19850388
Biomark Med. 2010 Apr;4(2):265-80
pubmed: 20406069
Ann Intensive Care. 2020 Apr 28;10(1):51
pubmed: 32347418
Int J Exp Pathol. 2011 Jun;92(3):168-92
pubmed: 20681980
Am J Pathol. 1992 Apr;140(4):831-8
pubmed: 1562048
J Am Soc Nephrol. 2003 Aug;14(8):2199-210
pubmed: 12874476
J Am Soc Nephrol. 2008 Dec;19(12):2331-41
pubmed: 18815244
Int J Crit Illn Inj Sci. 2014 Jul;4(3):223-8
pubmed: 25337484
Biomed Res Int. 2013;2013:612032
pubmed: 23607092
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Cells. 2020 May 28;9(6):
pubmed: 32481548
Glycobiology. 1997 Jun;7(4):499-506
pubmed: 9184830
Am J Kidney Dis. 2004 Mar;43(3):405-14
pubmed: 14981598
Pediatr Nephrol. 2013 Feb;28(2):237-43
pubmed: 22836304
Pediatr Nephrol. 2008 Jun;23(6):897-904
pubmed: 18278521
Front Med (Lausanne). 2021 Mar 01;8:639103
pubmed: 33732720
Pediatr Nephrol. 2018 Apr;33(4):553-571
pubmed: 28286898
Nephron Exp Nephrol. 2006;102(2):e49-61
pubmed: 16179830
JAMA Netw Open. 2020 Oct 1;3(10):e2019209
pubmed: 33021646
Clin J Am Soc Nephrol. 2010 Aug;5(8):1497-505
pubmed: 20558561